Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating high-dose viloxazine ER (SPN-812) in adolescents with ADHD has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPN-812 (viloxazine)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2021-07-02